Background: We sought to compare the benefits and safety of 6 biologics (abatacept,
adalimumab, anakinra, etanercept, infliximab and rituximab) in patients with rheumatoid
arthritis. Methods: In this network meta-analysis, we included all completed and updated
Cochrane reviews on biologics for rheumatoid arthritis. We included data from all placebo-
controlled trials that used standard dosing regimens. The major outcomes were benefit
(defined as a 50% improvement in patient-and physician-reported criteria of the American …

Background The biologic disease‐modifying anti‐rheumatic drugs (DMARDs) are very
effective in treating rheumatoid arthritis (RA), however there is a lack of head‐to‐head
comparison studies. Objectives To compare the efficacy and safety of abatacept,
adalimumab, anakinra, etanercept, infliximab, and rituximab in patients with RA. Methods
This 'Overview of Reviews' was done by including all Cochrane Reviews on Biologics for RA
available in The Cochrane Library. We included only data on standard dosing regimens for …